Kilquist syndrome

Summary

Kilquist syndrome (MONDO:0033664) is a disease caused by SLC12A2 (GenCC Strong), with 1 cohort gene.

At a glance

• Causal gene: SLC12A2 (GenCC Strong)
• Cohort genes: 1
• ClinVar variants: 51

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Kilquist syndrome
Mondo ID	MONDO:0033664
OMIM	619080
Orphanet	633021
UMLS	C5436756
MedGen	1742639
GARD	0027953
Is cancer (heuristic)	no

Also known as: KILQS · SLC12A2-related autosomal recessive neonatal-developmental delay-intellectual disability-feeding difficulty-sensorineural deafness syndrome

Data availability: 51 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › Kilquist syndrome

Related subtypes (218): immunodeficiency-centromeric instability-facial anomalies syndrome, hypercalcemia, infantile, Ochoa syndrome, autosomal recessive Ehlers-Danlos syndrome, vascular type, hydrolethalus syndrome, 3-M syndrome, isolated hyperchlorhidrosis, dacryocystitis-osteopoikilosis syndrome, Hutchinson-Gilford progeria syndrome, achalasia microcephaly syndrome, acrorenal syndrome, autosomal recessive, beta-ketothiolase deficiency, autosomal recessive Alport syndrome, Alstrom syndrome, microphthalmia with limb anomalies, camptodactyly-arthropathy-coxa vara-pericarditis syndrome, Behr syndrome, bifid nose, autosomal recessive, Bloom syndrome, Bowen-Conradi syndrome, camptodactyly with fibrous tissue hyperplasia and skeletal dysplasia, heart defects-limb shortening syndrome, autosomal recessive palmoplantar keratoderma and congenital alopecia, COFS syndrome, craniometaphyseal dysplasia, autosomal recessive, Fraser syndrome, cystic fibrosis, polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly, persistent hyperplastic primary vitreous, autosomal recessive, Donnai-Barrow syndrome, Schöpf-Schulz-Passarge syndrome, cleft lip/palate-ectodermal dysplasia syndrome, Ellis-van Creveld syndrome, Wolcott-Rallison syndrome, autosomal recessive faciodigitogenital syndrome, acromesomelic dysplasia 2B, brittle cornea syndrome, triple-A syndrome, autosomal recessive humeroradial synostosis, multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome, hydrocephalus, nonsyndromic, autosomal recessive 1, autosomal recessive hydrocephalus due to congenital stenosis of aqueduct of Sylvius, hypertelorism, microtia, facial clefting syndrome, hypoparathyroidism-retardation-dysmorphism syndrome, Vici syndrome, Johanson-Blizzard syndrome, autosomal recessive Kenny-Caffey syndrome, Papillon-Lefevre disease, Haim-Munk syndrome, Laurence-Moon syndrome, Donohue syndrome, lipase deficiency, combined, autosomal recessive familial Mediterranean fever, thiamine-responsive megaloblastic anemia syndrome, cartilage-hair hypoplasia, Nijmegen breakage syndrome, pseudo-TORCH syndrome, Galloway-Mowat syndrome, mulibrey nanism, myotonia congenita, autosomal recessive, Schwartz-Jampel syndrome, proteosome-associated autoinflammatory syndrome, Netherton syndrome, Niemann-Pick disease type A, oculodentodigital dysplasia, autosomal recessive, odonto-onycho-dermal dysplasia, autosomal recessive omodysplasia, osteoporosis-pseudoglioma syndrome, Shwachman-Diamond syndrome, phenylketonuria, Bjornstad syndrome, Laron syndrome, autosomal recessive polycystic kidney disease, autosomal recessive inherited pseudoxanthoma elasticum, autosomal recessive multiple pterygium syndrome, rapadilino syndrome, short-rib thoracic dysplasia 9 with or without polydactyly, autosomal recessive Robinow syndrome, Sjogren-Larsson syndrome, scapuloperoneal spinal muscular atrophy, autosomal recessive, spondyloepiphyseal dysplasia tarda, autosomal recessive, inherited threoninemia, Pendred syndrome, autosomal recessive spondylocostal dysostosis, Werner syndrome, ABCD syndrome, Naxos disease, autosomal recessive amelia, human HOXA1 syndromes, sickle cell disease, autosomal recessive proximal renal tubular acidosis, hyper-IgM syndrome type 2, temtamy preaxial brachydactyly syndrome, TH-deficient dopa-responsive dystonia, craniosynostosis syndrome, autosomal recessive, Niemann-Pick disease type B, skin fragility-woolly hair-palmoplantar keratoderma syndrome, CoQ-responsive OXPHOS deficiency, familial adenomatous polyposis 2, Pierson syndrome, palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome, cardiomyopathy-hypotonia-lactic acidosis syndrome, PHARC syndrome, Kahrizi syndrome, cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies, congenital prothrombin deficiency, immunodeficiency 31B, dyskeratosis congenita, autosomal recessive 2, dyskeratosis congenita, autosomal recessive 3, Nestor-Guillermo progeria syndrome, leukoencephalopathy with calcifications and cysts, mitochondrial pyruvate carrier deficiency, branched-chain keto acid dehydrogenase kinase deficiency, dyskeratosis congenita, autosomal recessive 5, hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome, alacrima, achalasia, and intellectual disability syndrome, hyperlipoproteinemia, type 1D, microcephaly and chorioretinopathy 2, congenital stationary night blindness 1G, combined oxidative phosphorylation deficiency 29, hypermanganesemia with dystonia 2, growth retardation, intellectual developmental disorder, hypotonia, and hepatopathy, gnb5-related intellectual disability-cardiac arrhythmia syndrome, autosomal recessive spastic paraplegia type 78, autosomal recessive limb-girdle muscular dystrophy, Bardet-Biedl syndrome, autosomal recessive cerebellar ataxia, neuronopathy, distal hereditary motor, autosomal recessive, UV-sensitive syndrome, Ehlers-Danlos syndrome, kyphoscoliotic type 1, Cockayne syndrome, hyperphenylalaninemia due to tetrahydrobiopterin deficiency, leukoencephalopathy-palmoplantar keratoderma syndrome, autosomal recessive hypohidrotic ectodermal dysplasia, Warburg micro syndrome, autosomal recessive primary microcephaly, autosomal recessive progressive external ophthalmoplegia, Meier-Gorlin syndrome, autosomal recessive sideroblastic anemia, autosomal recessive intermediate Charcot-Marie-Tooth disease, Perrault syndrome, autosomal recessive hypophosphatemic rickets, de Barsy syndrome, leukocyte adhesion deficiency, Senior-Loken syndrome, autosomal recessive spastic ataxia, childhood-onset autosomal recessive myopathy with external ophthalmoplegia, autosomal recessive cerebral atrophy, GM3 synthase deficiency, autosomal recessive distal renal tubular acidosis, pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome, autosomal recessive brachyolmia, Aicardi-Goutieres syndrome, homocystinuria without methylmalonic aciduria, Niemann-Pick disease type C, nephronophthisis, autosomal recessive osteopetrosis, peroxisome biogenesis disorder, congenital non-bullous ichthyosiform erythroderma, Seckel syndrome, Usher syndrome, autosomal recessive cutis laxa type 1, autosomal recessive cutis laxa type 2, hearing loss, autosomal recessive, microcephaly, growth restriction, and increased sister chromatid exchange 2, encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 1, congenital vertebral-cardiac-renal anomalies syndrome, hair defect with photosensitivity and intellectual disability syndrome, autosomal recessive severe congenital neutropenia, severe combined immunodeficiency due to CARMIL2 deficiency, extraoral halitosis due to methanethiol oxidase deficiency, neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities, mitochondrial complex 2 deficiency, nuclear type 3, mitochondrial complex 2 deficiency, nuclear type 4, mismatch repair cancer syndrome, spondyloepimetaphyseal dysplasia with joint laxity, type 3, Duane anomaly-myopathy-scoliosis syndrome, autosomal recessive axonal charcot-marie-tooth disease due to copper metabolism defect, immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome, optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome, congenital myopathy with reduced type 2 muscle fibers, NAD(P)HX dehydratase deficiency, autosomal recessive ocular albinism, ichthyosis linearis circumflexa, eosinophil peroxidase deficiency, hyperphenylalaninemia due to DNAJC12 deficiency, autosomal recessive epidermolytic ichthyosis, Ehlers-Danlos syndrome, classic-like, 2, joint laxity, short stature, and myopia, HELIX syndrome, auditory neuropathy-optic atrophy syndrome, glycosylphosphatidylinositol biosynthesis defect 15, neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, SCN4A-related myopathy, autosomal recessive, Uner Tan Syndrome, nephropathic cystinosis, Imerslund-Grasbeck syndrome type 1, Imerslund-Grasbeck syndrome type 2, permanent neonatal diabetes mellitus 1, growth hormone insensitivity with immune dysregulation 1, autosomal recessive, Rajab interstitial lung disease with brain calcifications 1, Roberts-SC phocomelia syndrome, neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities, RPE65-related recessive retinopathy, GUCY2D-related recessive retinopathy, autosomal recessive titinopathy, intellectual disability, autosomal recessive, ALPL-related autosomal recessive hypophosphatasia, spastic paraplegia 18b, autosomal recessive, CEP164-related ciliopathy, RP1-related recessive retinopathy, pseudohypoaldosteronism, type IB2, autosomal recessive, pseudohypoaldosteronism, type IB3, autosomal recessive, spastic paraplegia 30B, autosomal recessive, cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 1, brain small vessel disease 2B, autosomal recessive, IMPG1-related recessive retinopathy, PROM1-related recessive retinopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

51 retrieved; paginated sample, class counts are floors:

19 uncertain significance, 10 benign/likely benign, 8 likely benign, 6 conflicting classifications of pathogenicity, 5 pathogenic, 2 likely pathogenic, 1 benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
3064190	NM_001046.3(SLC12A2):c.2617-2A>G	SLC12A2	Pathogenic	criteria provided, single submitter
617506	Single allele	SLC12A2	Pathogenic	criteria provided, single submitter
984662	NM_001046.3(SLC12A2):c.1431del (p.Phe477fs)	SLC12A2	Pathogenic	no assertion criteria provided
984663	NM_001046.3(SLC12A2):c.2006-1G>A	SLC12A2	Pathogenic	no assertion criteria provided
984673	NC_000005.9:g.127441491_127471419delinsATGAAAAGCTTTACAGAAGTTGGAATTAAAAAAA	SLC12A2	Pathogenic	no assertion criteria provided
3064984	NM_001046.3(SLC12A2):c.959C>A (p.Ser320Ter)	SLC12A2	Likely pathogenic	criteria provided, single submitter
3780607	NM_001046.3(SLC12A2):c.3147G>A (p.Trp1049Ter)	SLC12A2	Likely pathogenic	criteria provided, single submitter
1385353	NM_001046.3(SLC12A2):c.288GGC[10] (p.Ala105_Ala107dup)	LOC129994526	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1335592	NM_001046.3(SLC12A2):c.953-7C>T	SLC12A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1671022	NM_001046.3(SLC12A2):c.562GGC[6] (p.Gly192dup)	SLC12A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1941803	NM_001046.3(SLC12A2):c.2894C>A (p.Ser965Tyr)	SLC12A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2169828	NM_001046.3(SLC12A2):c.476C>T (p.Ala159Val)	SLC12A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2287133	NM_001046.3(SLC12A2):c.3134C>T (p.Thr1045Ile)	SLC12A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1365125	NM_001046.3(SLC12A2):c.41G>T (p.Gly14Val)	LOC129994526	Uncertain significance	criteria provided, multiple submitters, no conflicts
1440806	NM_001046.3(SLC12A2):c.288GGC[11] (p.Ala104_Ala107dup)	LOC129994526	Uncertain significance	criteria provided, multiple submitters, no conflicts
1510335	NM_001046.3(SLC12A2):c.235A>C (p.Ser79Arg)	LOC129994526	Uncertain significance	criteria provided, multiple submitters, no conflicts
1373721	NM_001046.3(SLC12A2):c.3622C>G (p.Leu1208Val)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1385672	NM_001046.3(SLC12A2):c.788A>C (p.Glu263Ala)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1401954	NM_001046.3(SLC12A2):c.2293C>G (p.Leu765Val)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1445687	NM_001046.3(SLC12A2):c.2848G>A (p.Val950Met)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1473763	NM_001046.3(SLC12A2):c.2210T>A (p.Leu737Gln)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1476334	NM_001046.3(SLC12A2):c.1127A>G (p.Asn376Ser)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1505967	NM_001046.3(SLC12A2):c.881G>A (p.Arg294His)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1679711	NM_001046.3(SLC12A2):c.3566C>T (p.Ala1189Val)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1679744	NM_001046.3(SLC12A2):c.1226T>C (p.Ile409Thr)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
2156078	NM_001046.3(SLC12A2):c.376A>T (p.Ser126Cys)	SLC12A2	Uncertain significance	criteria provided, multiple submitters, no conflicts
3064550	NM_001046.3(SLC12A2):c.2756T>C (p.Val919Ala)	SLC12A2	Uncertain significance	criteria provided, single submitter
3065515	NM_001046.3(SLC12A2):c.2361T>G (p.Phe787Leu)	SLC12A2	Uncertain significance	criteria provided, single submitter
3892444	NM_001046.3(SLC12A2):c.2888A>G (p.Asp963Gly)	SLC12A2	Uncertain significance	criteria provided, single submitter
3892445	NM_001046.3(SLC12A2):c.3131C>T (p.Thr1044Met)	SLC12A2	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 8 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
SLC12A2	Strong	Autosomal recessive	Kilquist syndrome	8

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SLC12A2	Orphanet:633021	SLC12A2-related autosomal recessive neonatal-developmental delay-intellectual disability-feeding difficulty-sensorineural deafness syndrome
SLC12A2	Orphanet:633024	SLC12A2-related autosomal dominant infantile-developmental delay-intellectual disability-sensorineural deafness syndrome

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SLC12A2	HGNC:10911	ENSG00000064651	P55011	Solute carrier family 12 member 2	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SLC12A2	Solute carrier family 12 member 2	Cation-chloride cotransporter which mediates the electroneutral transport of chloride, potassium and/or sodium ions across the membrane.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SLC12A2	Other/Unknown	no		SLC12A1/SLC12A2, NKCC1, AA-permease/SLC12A_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
inferior vagus X ganglion	1
palpebral conjunctiva	1
parotid gland	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SLC12A2	277	ubiquitous	marker	palpebral conjunctiva, parotid gland, inferior vagus X ganglion

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SLC12A2	2,461

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SLC12A2	P55011	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 4. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Cation-coupled Chloride cotransporters	1	1631.4×	0.002	SLC12A2
R-HSA-425393	1	129.8×	0.015	SLC12A2
SLC-mediated transmembrane transport	1	59.2×	0.023	SLC12A2
Transport of small molecules	1	25.1×	0.040	SLC12A2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of cell volume	1	16852.0×	7e-04	SLC12A2
inorganic anion import across plasma membrane	1	8426.0×	7e-04	SLC12A2
inorganic cation import across plasma membrane	1	8426.0×	7e-04	SLC12A2
positive regulation of aspartate secretion	1	8426.0×	7e-04	SLC12A2
regulation of matrix metallopeptidase secretion	1	8426.0×	7e-04	SLC12A2
regulation of spontaneous synaptic transmission	1	4213.0×	0.001	SLC12A2
negative regulation of vascular wound healing	1	3370.4×	0.001	SLC12A2
transepithelial ammonium transport	1	3370.4×	0.001	SLC12A2
transepithelial chloride transport	1	1872.4×	0.001	SLC12A2
ammonium transmembrane transport	1	1872.4×	0.001	SLC12A2
hyperosmotic response	1	1685.2×	0.001	SLC12A2
intracellular chloride ion homeostasis	1	1685.2×	0.001	SLC12A2
chloride ion homeostasis	1	1532.0×	0.001	SLC12A2
T cell chemotaxis	1	1123.5×	0.002	SLC12A2
cellular response to potassium ion	1	1053.2×	0.002	SLC12A2
intracellular potassium ion homeostasis	1	991.3×	0.002	SLC12A2
cellular response to chemokine	1	991.3×	0.002	SLC12A2
sodium ion homeostasis	1	936.2×	0.002	SLC12A2
intracellular sodium ion homeostasis	1	766.0×	0.002	SLC12A2
potassium ion homeostasis	1	766.0×	0.002	SLC12A2
sodium ion import across plasma membrane	1	624.1×	0.002	SLC12A2
cell volume homeostasis	1	601.9×	0.002	SLC12A2
gamma-aminobutyric acid signaling pathway	1	543.6×	0.002	SLC12A2
maintenance of blood-brain barrier	1	481.5×	0.003	SLC12A2
potassium ion import across plasma membrane	1	366.4×	0.003	SLC12A2
chloride transmembrane transport	1	237.3×	0.005	SLC12A2
sodium ion transmembrane transport	1	203.0×	0.005	SLC12A2
transport across blood-brain barrier	1	179.3×	0.006	SLC12A2
monoatomic ion transport	1	156.0×	0.006	SLC12A2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SLC12A2	BUMETANIDE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SLC12A2	1	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BUMETANIDE	4	SLC12A2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SLC12A2	13	Binding:9, Functional:4

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BUMETANIDE	4	SLC12A2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	SLC12A2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.